Several oral tyrosine–kinase inhibitors (TKI) have also demonstrated activity for STS, including multi-TKI pazopanib for non-adipocytic STS [9], anaplastic lymphoma kinase (ALK) inhibitors for myofibroblastic tumors with ALK fusions [10], and cediranib for alveolar soft part sarcoma (ASPS) [11]. Here, ALK is linked to alveolar soft part sarcoma.